Clinical Trial Update: Olodaterol Bridging Study in Asthma [Phase 2]

View source ↗

Summary

The Phase 2 olodaterol bridging study in asthma sponsored by Boehringer Ingelheim has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Striverdi Respimat (olodaterol)
• olodaterol (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: WITHDRAWN